{
  "url": "https://finance.yahoo.com/news/sethera-therapeutics-unveils-breakthrough-enzymatic-155500792.html",
  "authorsByline": "Newsfile Corp.",
  "articleId": "70dfb8787ecc4eb4863aa8a2aa845ae4",
  "source": {
    "domain": "finance.yahoo.com",
    "location": {
      "country": "us",
      "state": "CA",
      "county": "Santa Clara County",
      "city": "Sunnyvale",
      "coordinates": {
        "lat": 37.3688301,
        "lon": -122.036349
      }
    }
  },
  "imageUrl": "https://media.zenfs.com/en/newsfile_64/b57597295cad24a0fa23c3669ac9942f",
  "country": "us",
  "language": "en",
  "pubDate": "2025-08-21T15:55:00+00:00",
  "addDate": "2025-08-21T16:10:07.307280+00:00",
  "refreshDate": "2025-08-21T16:10:07.307282+00:00",
  "score": 1.0,
  "title": "Sethera Therapeutics Unveils Breakthrough Enzymatic Platform for Next-Generation Peptide Drugs",
  "description": "Salt Lake City, Utah--(Newsfile Corp. - August 21, 2025) - Sethera Therapeutics today announced publication in the Proceedings of the National Academy of Sciences (PNAS) of peer-reviewed results describing an enzymatic crosslinking platform that forges durable thioether \"staples,\" locking peptides into drug-like cyclic architectures. The platform works across a broad range of substrates, including sequences built entirely from ...",
  "content": "Salt Lake City, Utah--(Newsfile Corp. - August 21, 2025) - Sethera Therapeutics today announced publication in the Proceedings of the National Academy of Sciences (PNAS) of peer-reviewed results describing an enzymatic crosslinking platform that forges durable thioether \"staples,\" locking peptides into drug-like cyclic architectures. The platform works across a broad range of substrates, including sequences built entirely from non-natural building blocks, delivering exceptional versatility, expanding accessible chemical space, and enabling the design of next-generation peptide therapeutics.\n\nTo view the full announcement, including downloadable images, bios, and more, click here.\n\u2022 Radical-Based Enzymatic Technology: Sethera's breakthrough platform acts like a precise \"molecular stapler,\" creating durable thioether \"staples\" that are chemically robust and protease-resistant - superior to traditional disulfide bonds found in natural peptides.\n\u2022 Controlled \"Promiscuity\" with Precision: The platform shows broad substrate scope, accepting non-natural building blocks (D-amino acids, -amino acids, N-methyl residues) while directing exactly where bonds form - expanding accessible chemical space for next-generation therapeutics.\n\u2022 PNAS Publication Validates Impact: Peer-reviewed results in Proceedings of the National Academy of Sciences demonstrate the technology's potential to lead the next wave of innovation in peptide therapeutics, directly connecting to GLP-1s, insulins, and natural hormone design.\n\n\n\nAbout Sethera Therapeutics\n\n\n\nSethera Therapeutics is developing internal programs and collaborations that leverage its enzymatic macrocyclization platform to create more effective, stable, and deliverable peptide medicines. By opening vast new design space and offering precise architectural control, Sethera is positioned to help lead the next wave of innovation in peptide therapeutics.\n\nTo view the source version of this press release, please visit https://www.newsfilecorp.com/release/263354",
  "medium": "Article",
  "links": [
    "https://api.newsfilecorp.com/redirect/YEAzRIbYaa",
    "https://api.newsfilecorp.com/redirect/gJvx0U8eKM",
    "https://api.newsfilecorp.com/redirect/0pBKEuPKoX",
    "https://api.newsfilecorp.com/redirect/pp14KuXbNA"
  ],
  "labels": [],
  "claim": "",
  "verdict": "",
  "keywords": [
    {
      "name": "natural peptides",
      "weight": 0.09431481
    },
    {
      "name": "non-natural building blocks",
      "weight": 0.08886157
    },
    {
      "name": "Breakthrough Enzymatic Platform",
      "weight": 0.08882127
    },
    {
      "name": "peptide therapeutics",
      "weight": 0.08706417
    },
    {
      "name": "natural hormone design",
      "weight": 0.07831748
    },
    {
      "name": "peptides",
      "weight": 0.07614324
    },
    {
      "name": "vast new design space",
      "weight": 0.07482388
    },
    {
      "name": "Sethera Therapeutics",
      "weight": 0.073566906
    },
    {
      "name": "accessible chemical space",
      "weight": 0.07339587
    },
    {
      "name": "broad substrate scope",
      "weight": 0.06892601
    }
  ],
  "topics": [],
  "categories": [],
  "taxonomies": [
    {
      "name": "/Business & Industrial/Pharmaceuticals & Biotech",
      "score": 0.927734375
    },
    {
      "name": "/News/Business News/Company News",
      "score": 0.85107421875
    },
    {
      "name": "/Health/Health Foundations & Medical Research",
      "score": 0.62744140625
    },
    {
      "name": "/News/Health News",
      "score": 0.338134765625
    },
    {
      "name": "/Health/Pharmacy/Drugs & Medications",
      "score": 0.310791015625
    }
  ],
  "sentiment": {
    "positive": 0.6968903,
    "negative": 0.022227172,
    "neutral": 0.28088257
  },
  "summary": "Sethera Therapeutics has unveiled a breakthrough Enzymatic Platform for Next-Generation Peptide Drugs. The platform uses a powerful enzymatic crosslinking system to create durable thioether \"staples\" that lock peptides into drug-like cyclic architecture. It can be applied to a wide range of substrates, including sequences from non-natural building blocks, and expands accessible chemical space for next-generation peptide therapeutics. The company is developing internal programs and collaborations to create more effective, stable, and deliverable peptide medicines.",
  "shortSummary": "Sethera Therapeutics unveiled a breakthrough enzymatic crosslinking platform for next-generation peptide therapeutics, enabling versatility and precise architectural control, with potential for future drug innovation.",
  "translation": "",
  "translatedTitle": "",
  "translatedDescription": "",
  "translatedSummary": "",
  "reprint": false,
  "reprintGroupId": "0aca058936384472a2b7cb0e01234dae",
  "places": [],
  "scraped_sources": [
    {
      "url": "https://api.newsfilecorp.com/redirect/0pBKEuPKoX",
      "text": "Sethera Therapeutics Unveils Breakthrough Enzymatic Platform for Next-Generation Peptide Drugs\nAugust 21, 2025 11:55 AM EDT | Source: Reportable, Inc.\nSalt Lake City, Utah--(Newsfile Corp. - August 21, 2025) - Sethera Therapeutics today announced publication in the Proceedings of the National Academy of Sciences (PNAS) of peer-reviewed results describing an enzymatic crosslinking platform that forges durable thioether \"staples,\" locking peptides into drug-like cyclic architectures. The platform works across a broad range of substrates, including sequences built entirely from non-natural building blocks, delivering exceptional versatility, expanding accessible chemical space, and enabling the design of next-generation peptide therapeutics.\nTo view the full announcement, including downloadable images, bios, and more, click here.\nKey Takeaways:\n- Radical-Based Enzymatic Technology: Sethera's breakthrough platform acts like a precise \"molecular stapler,\" creating durable thioether \"staples\" that are chemically robust and protease-resistant - superior to traditional disulfide bonds found in natural peptides.\n- Controlled \"Promiscuity\" with Precision: The platform shows broad substrate scope, accepting non-natural building blocks (D-amino acids, -amino acids, N-methyl residues) while directing exactly where bonds form - expanding accessible chemical space for next-generation therapeutics.\n- PNAS Publication Validates Impact: Peer-reviewed results in Proceedings of the National Academy of Sciences demonstrate the technology's potential to lead the next wave of innovation in peptide therapeutics, directly connecting to GLP-1s, insulins, and natural hormone design.\nClick image above to view full announcement.\nAbout Sethera Therapeutics\nSethera Therapeutics is developing internal programs and collaborations that leverage its enzymatic macrocyclization platform to create more effective, stable, and deliverable peptide medicines. By opening vast new design space and offering precise architectural control, Sethera is positioned to help lead the next wave of innovation in peptide therapeutics.\nContacts:\nKarsten Eastman, PhD, CEO\n385-461-8528\nbd@setheratx.com\nSource: Sethera Therapeutics\nTo view the source version of this press release, please visit https://www.newsfilecorp.com/release/263354"
    },
    {
      "url": "https://api.newsfilecorp.com/redirect/YEAzRIbYaa",
      "text": "Bios\nCynthia Tsai is a seasoned business leader with expertise in finance and entrepreneurship. She is Chairman of the Board of Sethera Therapeutics, a company developing innovative peptide therapies. Tsai's background includes 16 years on Wall Street with Merrill Lynch and General Electric. Previously, she was a General Partner of MassTech Ventures, an MIT-focused fund.\nTsai is President of the Board of Montana BioScience Alliance and serves on the Board of Directors of Ethan Allen.\nhttps://cdn.filestackcontent.com/L8qbFn2gQcCrQYDHqARs\nDr. Eastman received a PhD from the University of Utah under the mentorship of Professor Vahe Bandarian, where they discovered the key processes that enable Sethera Therapeutics\u2019 innovative technology.\nAs a co-founder of Sethera, Dr. Eastman is leading the company\u2019s efforts to commercialize cutting-edge peptide therapeutics, drawing on their experience in enzyme and peptide research, patent development, and engagement with key business mentors.\nhttps://cdn.filestackcontent.com/w0PLN1cSgC9FdxoTPhA2\nProfessor Vahe Bandarian is a distinguished faculty member and Associate Dean at the University of Utah, recognized for his exceptional contributions to the field of chemistry. He is a Fellow of the American Chemical Society (ACS), the American Association for the Advancement of Science (AAAS), and the American Society for Biochemistry and Molecular Biology (ASBMB).\nHis groundbreaking research has earned him the prestigious Pfizer Award in Enzyme Chemistry from the ACS and the Distinguished Research Award from the University of Utah.\nhttps://cdn.filestackcontent.com/nkKkIfrwTbKvbVlz9XS0\nExperienced scientist with a demonstrated expertise in protein engineering and its application in Biotechnology. Strong research professional skilled in computational protein design, experimental protein biochemistry, molecular biology, and bioinformatics. Trained with Nobel Laureate David Baker in protein design and has greater than 10 years of experience working with both large and small companies.\nhttps://cdn.filestackcontent.com/x1nw4biERdCcjnEQjjxu\nOver a decade of experience in recombinant protein technology with emphasis on synthesis, purification and characterization. Diversified educational background and research in collaborative environment resulted in successful completion of numerous projects. Used computational and data processing skills to develop several high-throughput screening methods for biomolecules. Developed strong leadership and problem-solving skills while mentoring multiple researchers throughout professional career.\nhttps://cdn.filestackcontent.com/cMek10vnQSCVfrVmncUF\nMaterializing ambitious ideas to answer complex scientific questions and push forward technological innovation. Extensive experience in cutting edge experimental and computational biology, chemistry and physics with an advanced mathematical and theoretical background from a rigorous training in physical chemistry.\nCurrently a molecular biologist focused on cancer profiling and evolution. Parallel ventures in game theory, quantum computing, fluid dynamics and AI.\nhttps://cdn.filestackcontent.com/GowhcAVnQFm6gEO7MEuq"
    },
    {
      "url": "https://api.newsfilecorp.com/redirect/gJvx0U8eKM",
      "text": "SALT LAKE CITY, Utah August 21, 2025 \u2014 Sethera Therapeutics today announced publication in the Proceedings of the National Academy of Sciences (PNAS) of peer-reviewed results describing an enzymatic crosslinking platform that forges durable thioether \u201cstaples,\u201d locking peptides into drug-like cyclic architectures. The platform works across a broad range of substrates, including sequences built entirely from non-natural building blocks, delivering exceptional versatility, expanding accessible chemical space, and enabling the design of next-generation peptide therapeutics.\nThe paper, titled \u201cDiverse Thioether Macrocyclized Peptides Through a Radical SAM Maturase,\u201d was co-authored by Sethera Therapeutics and collaborators in the Department of Chemistry at the University of Utah.\n\u201cMost people picture enzymes as molecular scissors,\u201d said Karsten Eastman, PhD, CEO and co-founder of Sethera. \u201cBut enzymes also build. Our radical-based enzymatic technology acts like a precise \u2018molecular stapler,\u2019 architecting new peptide structures and locking them into stable, drug-like shapes.\u201d\n\u201cBasic research matters,\u201d said Vahe Bandarian, PhD, Professor of Chemistry and Associate Provost for Mission-Aligned Planning at the University of Utah and co-founder of Sethera. \u201cUtah\u2019s translational ecosystem and sustained NIH support in fundamental chemistry and enzymology made this discovery possible. Sethera exemplifies how federal, state, and university partners turn bench science into unsurpassed societal impact.\"\nDefying the classic lock-and-key or induced-fit view of enzymes, Sethera\u2019s platform shows broad substrate scope with pinpoint bond placement, what scientists call controlled \u201cpromiscuity.\u201d The process reliably staples diverse peptide sequences and accepts non-natural building blocks, including D-amino acids, \u03b2-amino acids, and N-methyl residues, even enabling peptides composed entirely of non-natural components.\n\u201cWhat\u2019s distinctive here is breadth with precision, our technology handles many sequences while directing exactly where the bond forms,\u201d Eastman added.\nUnlike disulfide bonds found in many natural peptides (e.g., insulin), Sethera\u2019s thioether staples are chemically robust and protease-resistant, improving stability and pharmacological behavior and potentially supporting oral delivery. The team demonstrated reconstruction of sophisticated macrocyclic scaffolds often used to achieve passive cell permeability, accomplishing in a single enzymatic step what typically demands complex multi-step synthetic chemistry.\n\u201cGLP-1s are peptides; insulins are peptides; many natural hormones are peptides,\u201d Eastman said. \u201cThe platform we\u2019re building directly connects to designing the next generation of peptide therapeutics.\u201d\nAbout Sethera Therapeutics\nSethera Therapeutics is developing internal programs and collaborations that leverage its enzymatic macrocyclization platform to create more effective, stable, and deliverable peptide medicines. By opening vast new design space and offering precise architectural control, Sethera is positioned to help lead the next wave of innovation in peptide therapeutics.\nSethera Therapeutics\nKarsten Eastman, PhD, CEO\n385-461-8528 \u2022 bd@setheratx.com"
    },
    {
      "url": "https://api.newsfilecorp.com/redirect/pp14KuXbNA",
      "text": "SALT LAKE CITY, Utah August 21, 2025 \u2014 Sethera Therapeutics today announced publication in the Proceedings of the National Academy of Sciences (PNAS) of peer-reviewed results describing an enzymatic crosslinking platform that forges durable thioether \u201cstaples,\u201d locking peptides into drug-like cyclic architectures. The platform works across a broad range of substrates, including sequences built entirely from non-natural building blocks, delivering exceptional versatility, expanding accessible chemical space, and enabling the design of next-generation peptide therapeutics.\nThe paper, titled \u201cDiverse Thioether Macrocyclized Peptides Through a Radical SAM Maturase,\u201d was co-authored by Sethera Therapeutics and collaborators in the Department of Chemistry at the University of Utah.\n\u201cMost people picture enzymes as molecular scissors,\u201d said Karsten Eastman, PhD, CEO and co-founder of Sethera. \u201cBut enzymes also build. Our radical-based enzymatic technology acts like a precise \u2018molecular stapler,\u2019 architecting new peptide structures and locking them into stable, drug-like shapes.\u201d\n\u201cBasic research matters,\u201d said Vahe Bandarian, PhD, Professor of Chemistry and Associate Provost for Mission-Aligned Planning at the University of Utah and co-founder of Sethera. \u201cUtah\u2019s translational ecosystem and sustained NIH support in fundamental chemistry and enzymology made this discovery possible. Sethera exemplifies how federal, state, and university partners turn bench science into unsurpassed societal impact.\"\nDefying the classic lock-and-key or induced-fit view of enzymes, Sethera\u2019s platform shows broad substrate scope with pinpoint bond placement, what scientists call controlled \u201cpromiscuity.\u201d The process reliably staples diverse peptide sequences and accepts non-natural building blocks, including D-amino acids, \u03b2-amino acids, and N-methyl residues, even enabling peptides composed entirely of non-natural components.\n\u201cWhat\u2019s distinctive here is breadth with precision, our technology handles many sequences while directing exactly where the bond forms,\u201d Eastman added.\nUnlike disulfide bonds found in many natural peptides (e.g., insulin), Sethera\u2019s thioether staples are chemically robust and protease-resistant, improving stability and pharmacological behavior and potentially supporting oral delivery. The team demonstrated reconstruction of sophisticated macrocyclic scaffolds often used to achieve passive cell permeability, accomplishing in a single enzymatic step what typically demands complex multi-step synthetic chemistry.\n\u201cGLP-1s are peptides; insulins are peptides; many natural hormones are peptides,\u201d Eastman said. \u201cThe platform we\u2019re building directly connects to designing the next generation of peptide therapeutics.\u201d\nAbout Sethera Therapeutics\nSethera Therapeutics is developing internal programs and collaborations that leverage its enzymatic macrocyclization platform to create more effective, stable, and deliverable peptide medicines. By opening vast new design space and offering precise architectural control, Sethera is positioned to help lead the next wave of innovation in peptide therapeutics.\nSethera Therapeutics\nKarsten Eastman, PhD, CEO\n385-461-8528 \u2022 bd@setheratx.com"
    }
  ],
  "argos_summary": "Sethera Therapeutics announced that its radical\u2011SAM enzymatic platform, which creates durable thioether staples to lock peptides into cyclic, drug\u2011like structures, has been validated in a peer\u2011reviewed PNAS paper. The technology works across a wide range of substrates, including fully non\u2011natural amino acid sequences, offering precise bond placement and broad \u201ccontrolled promiscuity.\u201d Compared to traditional disulfide bonds, the thioether staples are chemically robust and protease\u2011resistant, potentially improving stability, pharmacology, and oral delivery of peptide therapeutics such as GLP\u20111s and insulins. The platform expands accessible chemical space and positions Sethera to lead the next wave of peptide drug development, with support from the University of Utah and federal research funding.",
  "argos_id": "JASZ1XB3Z"
}